Results 121 to 130 of about 692,682 (292)
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 2020 Objective We aimed to examine the effects of adding a longer-acting insulin glargine to existing glucose control on reducing blood-glucose fluctuations in an intensive care unit (ICU).
N. Nader +7 more
semanticscholar +1 more source
Pneumoperitoneum in two cats treated with trilostane for hypercortisolism
Veterinary Record Case Reports, Volume 14, Issue 1, February 2026.Abstract This report describes two cases of pneumoperitoneum in cats receiving treatment for hypercortisolism and diabetes mellitus. Both cats presented with abdominal distention and lethargy and diagnoses of pneumoperitoneum were radiographically confirmed.
Nicholas James Kelly +4 more
wiley +1 more source
Therapeutic Advances in Endocrinology and Metabolism, 2012 The three currently marketed long-acting insulin analogs, glargine, detemir and insulin lispro protamine suspension (ILPS), represent the most significant advances in basal insulin supplementation since the 1940s and 1950s and the introduction of the ...
Dario Giugliano, Katherine Esposito
doaj +1 more source
Indian Journal of Endocrinology and Metabolism, 2014 Aim: To determine the safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) therapy in the Indian patients with type 2 diabetes previously on basal or basal-bolus insulin therapies.
Arpandev Bhattacharyya +3 more
doaj +1 more source
Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. [PDF]
, 2015 INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a treatment strategy for type 1 diabetes. Transition from multiple daily injection therapy (MDI; including basal-bolus regimens) to CSII is based on ...
Hovorka, R, Mohd-Thabit, HA
core +1 more source
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
BioDrugs, 2020 Subcutaneous MYL1501D insulin glargine 100 U/mL (hereafter referred to as MYL1501D insulin glargine) [Semglee ® ] is a long-acting human insulin analogue approved as a biosimilar of insulin glargine 100 U/mL (hereafter referred to as reference insulin ...
Sheridan M. Hoy
semanticscholar +1 more source
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami +2 more
wiley +1 more source
The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome [PDF]
, 2013 Articles in International JournalsFeline Chronic Gingivostomatitis Syndrome (FCGS) is a common disease in clinical practice. Among the therapeutic options available, long-acting corticosteroids are frequently used due to their anti-inflammatory and ...
A Domenech +22 more
core +2 more sources
Diabetes, obesity and metabolism, 2019 To compare the second‐generation basal insulin glargine 300 units/mL (Gla‐300) and first‐generation basal insulins on glycaemic control and hypoglycaemia risk in older adults with type 2 diabetes (T2D).
T. Bailey +8 more
semanticscholar +1 more source